Table 1. Patients evaluable 25 Age 56... | American Society of Hematology

Table 1.

Patients evaluable

25

Age

56 (range 37-71)

Sex (M/F)

22/3

Untreated

12

Previously treated:

13

α-IFN

7

2-CdA (standard regimen)

4

DCF

2

CR

19 (76%)

PR

6 (24%)

Median duration of CR

15 mo (range 3-31)

Severe neutropenia

4

Infectious complications

2